The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...

Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...

Please provide your email address to receive an email when new articles are posted on . AvaGen, the Genetic Eye Test, can be performed in the eye care practice, helping doctors help their patients ...

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

A new genetic cause of corneal dystrophy has been discovered with funding from Fight for Sight by researchers at UCL Institute of Ophthalmology and Moorfields Eye Hospital London, in collaboration ...

Because the condition was bilateral, a corneal dystrophy was suspected. Lattice dystrophy typically presents with branching refractile lattice lines with intervening haze, which are observed best ...

Bottom Line: Researchers discovered three novel genetic mutations associated with Fuchs endothelial corneal dystrophy, the most common corneal disorder requiring transplantation. Journal in Which the ...

Diabetes, especially type 1 diabetes, may be a particularly important factor in the etiology of Fuchs endothelial corneal dystrophy (FECD) in findings from a case-control study of about 149.000 US ...

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S.